Comparative Pharmacology
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus VIVACTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus VIVACTIL.
CLOMIPRAMINE HYDROCHLORIDE vs VIVACTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, with additional anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Oral, initial 25 mg three times daily; increase gradually to 100-250 mg/day in divided doses; maximum 300 mg/day for severe conditions.
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life of clomipramine is 19-37 hours (mean ~30 hours); active metabolite desmethylclomipramine has half-life of 54-77 hours. Steady-state achieved within 1-2 weeks.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Renal: ~60% (as conjugated metabolites and unchanged drug); Fecal: ~30% (biliary excretion); 2-3% excreted unchanged in urine.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant